Table 3 Treatment-emergent adverse events
From: Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression
Placebo ( N =39) | Low rilotumumab exposure ( N =40) | High rilotumumab exposure ( N =41) | Overall ( N =120) | |
|---|---|---|---|---|
Any AE | 39 (100.0) | 39 (97.5) | 41 (100.0) | 119 (99.2) |
Grade ⩾3 | 29 (74.4) | 36 (90.0) | 35 (85.4) | 100 (83.3) |
Serious AEs | 20 (51.3) | 25 (62.5) | 22 (53.7) | 67 (55.8) |
Fatal AEs | 6 (15.4) | 5 (12.5) | 4 (9.8) | 15 (12.5) |
Common grade ⩾3 AEs a | ||||
Neutropenia | 11 (28.2) | 15 (37.5) | 21 (51.2) | 47 (39.2) |
Anaemia | 5 (12.8) | 5 (12.5) | 7 (17.1) | 17 (14.2) |
Fatigue | 6 (15.4) | 7 (17.5) | 3 (7.3) | 16 (13.3) |
Vomiting | 4 (10.3) | 4 (10.0) | 3 (7.3) | 11 (9.2) |
Diarrhoea | 2 (5.1) | 2 (5.0) | 2 (4.9) | 6 (5.0) |
Palmar-plantar erythrodysesthesia syndrome | 2 (5.1) | 4 (10.0) | 3 (7.3) | 9 (7.5) |
Abdominal pain | 3 (7.7) | 1 (2.5) | 3 (7.3) | 7 (5.8) |
Hypokalemia | 3 (7.7) | 3 (7.5) | 3 (7.3) | 9 (7.5) |
Dehydration | 3 (7.7) | 2 (5.0) | 2 (4.9) | 7 (5.8) |
Pulmonary embolism | 4 (10.3) | 5 (12.5) | 2 (4.9) | 11 (9.2) |
Nausea | 3 (7.7) | 3 (7.5) | 2 (4.9) | 8 (6.7) |
Febrile neutropenia | 2 (5.1) | 4 (10.0) | 2 (4.9) | 8 (6.7) |
Deep vein thrombosis | 0 (0.0) | 5 (12.5) | 2 (4.9) | 7 (5.8) |
